Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into data

Janux Therapeutics (JANX) PT Raised to $115 at Stifel

December 3, 2024 8:22 AM EST

Stifel analyst Bradley Canino raised the price target on Janux Therapeutics (NASDAQ: JANX) to $115.00 (from $70.00) while maintaining a Buy rating.

The analyst comments "The JANX007 (PSMA-TRACTr) phase 1 update (LINK) leads us to increase our PoS for 2L and 3L mCRPC to 50% and 65%, respectively... More

William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'

December 3, 2024 7:06 AM EST

William Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).

The analyst comments "On Monday, December 2, Janux disclosed updated clinical results with JANX007, the companys PSMAxCD3 TRACTr bispecific T-cell engager, in patients with heavily pretreated metastatic castrate resistant prostate cancer (mCRPC), demonstrating... More

Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners

December 3, 2024 6:55 AM EST

Leerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More